NP’s comment regarding putting a hold on Mono for to pursue PreP is interesting. Mono therapy with a once a week injectable, possibly multiple weeks with refinement, is a huge deal and could be a very large market. For NP and CYDY to temporarily shelved Mono for PreP indicates some big interest in Leronlimab for Prep.

My one question is this: how can CYDY get BTD without any clinical data on PreP? Am I missing something? I’m assuming leronlimab would still have to complete a large clinical trial for PreP before getting approved.